News from nuvo research inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Dec 22, 2014, 07:30 ET

Nuvo Research® Granted Additional U.S. Patent for Treatment of Allergic Rhinitis with WF10™

MISSISSAUGA, ON, Dec. 22, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company with a diverse portfolio of...

Dec 18, 2014, 07:30 ET

Nuvo Research® reports that all patients have completed Phase 2 study of WF10™ for the treatment of allergic rhinitis

- Top-Line Results Expected in February 2015 - MISSISSAUGA, ON, Dec. 18, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX:NRI), a specialty...

Nov 13, 2014, 07:30 ET

Nuvo Research® reacquires Pennsaid® 2% rights to South America, Central America, South Africa and Israel

MISSISSAUGA, ON, Nov. 13, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of...

Nov 10, 2014, 17:00 ET

Nuvo Research® Announces 2014 Third Quarter Results

MISSISSAUGA, ON, Nov. 10, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of topical...

Nov 03, 2014, 00:01 ET

Nuvo Research® plans Phase 3 study of Pennsaid® 2% to support international regulatory approvals

MISSISSAUGA, ON, Nov. 3, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of topical...

Oct 22, 2014, 07:30 ET

Nuvo Research® Completes WF10™ U.S. Market Study for Treatment of Refractory Allergies

MISSISSAUGA, ON, Oct. 22, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of topical...

Oct 17, 2014, 07:00 ET

Nuvo Research® Sells PENNSAID® 2% U.S. Rights for US$45 Million to Horizon Pharma

-- Nuvo to Host Conference Call/Webcast at 8:30 a.m. ET -- MISSISSAUGA, ON, Oct. 17, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX:NRI), a specialty...

Sep 08, 2014, 07:30 ET

Nuvo Research® settles litigation with Mallinckrodt Pharmaceuticals

MISSISSAUGA, ON, Sept. 8, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of topical...

Sep 04, 2014, 07:30 ET

Nuvo Research® to Present at Rodman & Renshaw 16th Annual Global Investment Conference

MISSISSAUGA, ON, Sept. 4, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI) a specialty pharmaceutical company with a diverse portfolio of...

Sep 03, 2014, 07:30 ET

Nuvo Research® Completes Enrolment in WF10™ Phase 2 Clinical Trial

- Results Expected Q1 2015 - MISSISSAUGA, ON, Sept. 3, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical...

Jul 30, 2014, 17:00 ET

Nuvo Research® announces 2014 second quarter results

MISSISSAUGA, ON, July 30, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of...

Jun 17, 2014, 12:30 ET

Nuvo Research to present at Bloom Burton & Co Healthcare Investor Conference

MISSISSAUGA, ON, June 17, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI) a specialty pharmaceutical company with a diverse portfolio of...

Jun 11, 2014, 15:30 ET

Nuvo Research announces director election results of its annual general meeting

MISSISSAUGA, ON, June 11, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI) a specialty pharmaceutical company with a diverse portfolio of...

May 29, 2014, 08:00 ET

Nuvo Research® announces U.S. FDA approval of third-party generic of PENNSAID 1.5%

MISSISSAUGA, ON, May 29, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company with a diverse portfolio of...

Apr 30, 2014, 17:00 ET

Nuvo Research® announces 2014 first quarter results

MISSISSAUGA, ON, April 30, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of...

Apr 23, 2014, 07:30 ET

Nuvo Research Announces Collaboration to Develop Topical Dermatology Products

MISSISSAUGA, ON, April 23, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company with a diverse portfolio of...

Apr 01, 2014, 07:30 ET

Nuvo Research® closes $3.1 million private placement

MISSISSAUGA, ON, April 1, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX:NRI), (the "Company"), a specialty pharmaceutical company with a diverse...

Feb 20, 2014, 17:00 ET

Nuvo Research announces 2013 fourth quarter & year-end results

MISSISSAUGA, ON, Feb. 20, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company with a diverse portfolio of...

Feb 10, 2014, 08:00 ET

Nuvo Research Announces the U.S. Commercial Launch of PENNSAID® 2% by Mallinckrodt

MISSISSAUGA, ON, Feb. 10, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company with a diverse portfolio of...

Jan 17, 2014, 07:00 ET

Nuvo Research Announces FDA Approval of PENNSAID® 2%

- Mallinckrodt to Launch PENNSAID 2% in the U.S. in Q1 2014 - MISSISSAUGA, ON, Jan. 17, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX:NRI), a...